RNS Number:7020Q
Alizyme PLC
09 October 2003


Immediate Release                                                9 October 2003



ALIZYME ANNOUNCES GRANT OF USA PATENT FOR ATL-962 FOR THE TREATMENT OF OBESITY 
                        AND RELATED DISORDERS

Cambridge UK, 9 October 2003: Alizyme plc (LSE:AZM) is pleased to announce the
grant of a USA patent in relation to its development product ATL-962.

The USA patent includes composition of matter claims to a family of novel
compounds (including ATL-962) and their use in the treatment of obesity and
obesity related disorders, including Type II diabetes. This patent would be
expected to expire in January 2020.

On 19 September 2003, Alizyme reported the successful results of its Phase IIb
clinical trial of ATL-962 in 372 clinically obese patients.

Dr. Richard Palmer (Chief Executive Officer) commented:

"We are pleased to receive the grant of this patent in the USA which should
offer commercial protection for our obesity product, ATL-962, through to 2020 in
the world's largest market for pharmaceutical products."

For further information, please contact:

Dr Richard Palmer, Chief Executive Officer
Mr Tim McCarthy, Finance Director
ALIZYME plc                                          Tel No: + 44 (0)1223 896000

Lisa Baderoon                                         Mobile:+44 (0)7721 413 496
BUCHANAN COMMUNICATIONS                            Tel No: + 44 (0) 20 7466 5000

Further information on Alizyme can be found on the Company's website:
www.alizyme.com

                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCEADEPEDFDFAE